Detail akcie Illumina Inc online

Business Summary: Illumina, Inc. is a provider of sequencing and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Illumina Inc revenues decreased 2% to $4.5B. Net loss decreased 74% to $1.16B. Revenues reflect Greater China segment decrease of 19% to $384M, Europe, Middle East, and Africa segment decrease of 6% to $1.14B, Americas segment decrease of 14% to $162M. Lower net loss reflects GRAIL segment loss decrease of 65% to $1.62B, Core Illumina segment income increase of 15% to $552M.